Protocol 405-201-00013: A Phase 3 Randomized Double-blind Multicenter Placebo-controlled Parallel-group Trial Evaluating the Efficacy Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults with Attention-deficit/Hyperactivity Disorder

Brief description of study

To confirm the efficacy of centanafadine sustained-release (SR) tablets administered twice-daily (BID; 200 mg or 400 mg total daily doses [TDDs]) compared to placebo in the treatment of adults with ADHD and confirm the safety and tolerability of centanafadine SR tablets administered BID (200 mg or 400 mg TDDs) compared to placebo in the treatment of adults with ADHD. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called centanafadine sustained release (SR) for people with attention deficient hyperactivity disorder (ADHD). An investigational drug is a drug that is has not been approved by the United States Food and Drug Administration (FDA).

Clinical Study Identifier: s18-00372 Identifier: NCT03605680
Principal Investigator: Lenard A Adler
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.